Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

Esperion announced positive Phase 2 pediatric study results showing bempedoic acid (NEXLETOL) safely reduced LDL-C by 6-25% in children aged 6-17 with familial hypercholesterolemia. Additionally, a secondary analysis of CLEAR Outcomes found that 42% of statin-intolerant patients achieved ≥30% LDL-C reduction at 3 months, with enhanced results in women, patients with higher baseline LDL-C, and those using concurrent ezetimibe.